TScan Therapeutics, Inc. (TCRX) shareholders
Close on Nov 17, 2026Market cap $10.23MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Weston Nichols Joint filing with Lynx1 Capital Management LP (13.10%) | 20,519,148 | 13.10% | 13G (passive) amendment | Jun 30, 2026 |
| Lynx1 Capital Management LP Joint filing with Weston Nichols (15.00%) | 7,857,347 | 15.00% | 13G (passive) amendment | Jun 30, 2025 |
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (9.99%), Lampert Mark N (9.99%) and 3 more | 6,417,831 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (9.99%), Bvf Inc/Il (9.99%) and 3 more | 5,263,541 | 9.99% | 13G (passive) amendment | Mar 31, 2025 |
| Parag Shah Joint filing with K2 HealthVentures Equity Trust LLC (6.90%), Anup Arora (6.90%) | 3,602,700 | 6.90% | 13G (passive) amendment | Dec 31, 2024 |
| Phillip Gross Joint filing with Adage Capital Management, L.P. (7.13%), Robert Atchinson (7.13%) | 3,500,000 | 7.13% | 13G (passive) amendment | Dec 31, 2024 |
| Readout Capital, LP Joint filing with Readout Capital GP, LLC (5.40%), Matthew Smith (5.40%) | 3,453,388 | 5.40% | 13G (passive) | Sep 21, 2026 |
| Felix J. Baker Joint filing with Baker Bros. Advisors LP (6.10%), Baker Bros. Advisors (GP) LLC (6.10%) and 1 more | 2,828,938 | 6.10% | 13D (active) amendment | Apr 19, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TCRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 8,019,148 | 11.83% | $7.86M | – | 0.91% |
| Bvf Inc/Il | 5,564,290 | 8.21% | $5.45M | – | 0.14% |
| Baker Bros. Advisors LP | 2,784,792 | 4.11% | $2.73M | – | 0.01% |
| Vanguard Capital Management LLC | 2,158,831 | 3.19% | $2.12M | +4,575 | 0.00% |
| Two Sigma Investments, LP | 1,949,604 | 2.88% | $1.91M | +740,595 | 0.00% |
| Renaissance Technologies LLC | 1,326,799 | 1.96% | $1.30M | −37,984 | 0.00% |
| Acadian Asset Management LLC | 1,305,840 | 1.93% | $1.28M | +1,103,853 | 0.00% |
| Deer Management Co. LLC | 1,245,504 | 1.84% | $1.22M | – | 0.15% |
| Millennium Management LLC | 1,163,611 | 1.72% | $1.14M | −296,674 | 0.00% |
| Jacobs Levy Equity Management, Inc | 1,049,806 | 1.55% | $1.03M | +241,450 | 0.00% |
| Citadel Advisors LLC | 1,009,107 | 1.49% | $989.03K | +690,696 | 0.00% |
| BlackRock, Inc. | 994,654 | 1.47% | $974.86K | −846,298 | 0.00% |
| Kalehua Capital Management LLC | 909,752 | 1.34% | $891.65K | New | 0.28% |
| Boothbay Fund Management, LLC | 772,241 | 1.14% | $756.87K | New | 0.01% |
| Marshall Wace, Llp | 687,364 | 1.01% | $673.62K | +450,018 | 0.00% |
| DC Funds, LP | 630,000 | 0.93% | $617.46K | – | 49.27% |
| Geode Capital Management, LLC | 584,811 | 0.86% | $573.40K | −32,141 | 0.00% |
| D. E. Shaw & Co., Inc. | 548,402 | 0.81% | $537.49K | +228,815 | 0.00% |
| Gsa Capital Partners Llp | 548,087 | 0.81% | $537.00K | +169,127 | 0.03% |
| Vanguard Fiduciary Trust Co | 363,954 | 0.54% | $356.68K | +58,182 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 60 | 36M | 53.5% | 7 / 23 | 12 / 7 | 6M | 2M |
| Q1 2026 | 60 | 33M | 48.0% | 11 / 15 | 21 / 11 | 6M | 2M |
| Q4 2025 | 61 | 31M | 45.3% | 10 / 18 | 19 / 20 | 3M | 7M |
| Q3 2025 | 73 | 35M | 51.7% | 5 / 19 | 30 / 12 | 1M | 2M |
| Q2 2025 | 81 | 36M | 52.8% | 21 / 26 | 18 / 32 | 7M | 11M |
| Q1 2025 | 92 | 40M | 59.2% | 17 / 33 | 19 / 13 | 4M | 5M |
| Q4 2024 | 89 | 42M | 61.3% | 16 / 31 | 15 / 16 | 3M | 4M |
| Q3 2024 | 89 | 42M | 61.8% | 20 / 25 | 18 / 11 | 7M | 2M |
| Q2 2024 | 81 | 41M | 61.2% | 32 / 18 | 15 / 16 | 9M | 2M |
| Q1 2024 | 66 | 35M | 51.4% | 17 / 23 | 8 / 5 | 3M | 0M |
| Q4 2023 | 54 | 32M | 47.5% | 22 / 13 | 4 / 0 | 4M | 0M |
| Q3 2023 | 32 | 29M | 42.2% | 6 / 10 | 1 / 1 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
20 funds held TCRX in Q2 2026, 72% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TCRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,500,337 | 2.21% | $1.47M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 575,570 | 0.85% | $564.12K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 293,642 | 0.43% | $317.13K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 167,533 | 0.25% | $164.20K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 87,566 | 0.13% | $94.57K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 72,914 | 0.11% | $78.75K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 70,400 | 0.10% | $69.00K | 0.05% | Jun 30, 2026 |
| Multi-Manager Small Cap Equity Strategies Fund | 69,487 | 0.10% | $75.05K | 0.01% | May 31, 2026 |
| Small Cap Equity Fund | 65,813 | 0.10% | $64.50K | 0.01% | Jun 30, 2026 |
| NVIT Multi-Manager Small Company Fund | 44,500 | 0.07% | $43.61K | 0.01% | Jun 30, 2026 |
| NVIT Small Cap Value Fund | 39,000 | 0.06% | $38.22K | 0.02% | Jun 30, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 29,612 | 0.04% | $31.98K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 29,605 | 0.04% | $29.02K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 28,767 | 0.04% | $31.07K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 19,320 | 0.03% | $18.94K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Gavin MacBeath | Chief Executive Officer, Director | 1,049,767 | 1.55% | Oct 2, 2026 |
| Zoran Zdraveski | See Remarks | 304,716 | 0.45% | Oct 2, 2026 |
| Jason Amello | Chief Financial Officer | – | – | Jan 22, 2026 |
| Chrystal Louis | Chief Medical Officer | – | – | Jan 22, 2026 |
| Leiden Dworak | See Remarks | 5,692 | 0.01% | Jan 22, 2026 |
| Bros. Advisors (GP) LLC Baker | Director | – | – | May 22, 2026 |
| Keith Woods | Director | – | – | May 22, 2026 |
| 667, L.P. | Director | 256,209 | 0.38% | May 22, 2026 |
| Katina Dorton | Director | – | – | May 22, 2026 |
| Garry A. Nicholson | Director | – | – | May 22, 2026 |
| Gabriela Gruia | Director | – | – | May 22, 2026 |
| Barbara Klencke | Director | 70,000 | 0.10% | May 22, 2026 |
| Bros. Advisors Lp Baker | Director | – | – | May 22, 2026 |
| Julian Baker | Director | – | – | May 22, 2026 |
| Felix Baker | Director | – | – | May 22, 2026 |
| Brothers Life Sciences LP Baker | Director | – | – | May 22, 2026 |
| Weston Nichols | 10% owner | 5,357,347 | 7.90% | Dec 23, 2025 |
| Capital Management LP Lynx1 | 10% owner | 8,019,148 | 11.83% | Dec 23, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gavin MacBeath Chief Executive Officer, Director | Oct 1, 2026 | Award | +1,000,000 | – | – | 1,049,767 |
| Zoran Zdraveski See Remarks | Oct 1, 2026 | Award | +300,000 | – | – | 304,716 |
| Capital Management LP Lynx1 10% owner | Dec 23, 2025 | Buy | +6,232 | $0.90 | $5.61K | 8,019,148 |
| Capital Management LP Lynx1 10% owner | Dec 22, 2025 | Buy | +75,500 | $0.90 | $67.95K | 8,012,916 |
| Capital Management LP Lynx1 10% owner | Dec 19, 2025 | Buy | +80,069 | $0.90 | $72.06K | 7,937,416 |
| Capital Management LP Lynx1 10% owner | May 20, 2025 | Buy | +1,200,000 | $1.20 | $1.44M | 7,946,141 |
| Capital Management LP Lynx1 10% owner | May 19, 2025 | Buy | +1,388,794 | $1.20 | $1.67M | 6,746,141 |
| Weston Nichols 10% owner | Dec 13, 2024 | Buy | +100,000 | $2.90 | $290.00K | 5,357,347 |
| Weston Nichols 10% owner | Dec 12, 2024 | Buy | +31,800 | $3.01 | $95.72K | 5,257,347 |
| Weston Nichols 10% owner | Nov 15, 2024 | Buy | +947 | $4.34 | $4.11K | 5,225,547 |
| Barbara Klencke Director | Sep 23, 2024 | Buy | +5,000 | $5.29 | $26.45K | 45,000 |
| Barbara Klencke Director | Aug 26, 2024 | Buy | +5,000 | $5.53 | $27.65K | 40,000 |
| Zoran Zdraveski See Remarks | Aug 23, 2024 | Option exercise | +54,895 | $4.85 | $266.24K | 67,111 |
| Zoran Zdraveski See Remarks | Aug 23, 2024 | Option exercise | +25,000 | $3.27 | $81.75K | 92,111 |
| Zoran Zdraveski See Remarks | Aug 23, 2024 | Option exercise | +13,125 | $1.81 | $23.76K | 105,236 |
| Zoran Zdraveski See Remarks | Aug 23, 2024 | Option exercise | +64,166 | $2.49 | $159.77K | 169,402 |
| Zoran Zdraveski See Remarks | Aug 23, 2024 | Sale | −164,686 | $5.78 | $951.89K | 4,716 |
| Barbara Klencke Director | Aug 23, 2024 | Buy | +5,000 | $5.69 | $28.45K | 35,000 |
| Timothy J. Barberich Director | Dec 19, 2023 | Buy | +317 | $4.97 | $1.58K | 67,027 |
| Timothy J. Barberich Director | Dec 18, 2023 | Buy | +28,830 | $4.89 | $140.98K | 66,710 |
| Barbara Klencke Director | Dec 14, 2023 | Buy | +5,000 | $5.08 | $25.40K | 30,000 |
| Timothy J. Barberich Director | Jun 2, 2023 | Buy | +37,880 | $2.63 | $99.62K | 37,880 |
| Capital Management LP Lynx1 10% owner | May 31, 2023 | Sale | −15,000 | $2.52 | $37.80K | 5,225,000 |
| Capital Management LP Lynx1 10% owner | May 31, 2023 | Sale | −10,000 | $2.51 | $25.10K | 5,240,000 |
| Capital Management LP Lynx1 10% owner | May 31, 2023 | Sale | −400 | $2.51 | $1.00K | 5,224,600 |
| Brian M. Silver Chief Financial Officer | Dec 28, 2022 | Buy | +3,158 | $1.56 | $4.93K | 32,885 |
| Brian M. Silver Chief Financial Officer | Dec 27, 2022 | Buy | +2,842 | $1.50 | $4.26K | 29,727 |
| David P. Southwell Chief Executive Officer, Director | May 18, 2022 | Buy | +10,000 | $3.55 | $35.50K | 171,569 |
| David P. Southwell Chief Executive Officer, Director | May 18, 2022 | Buy | +15,000 | $3.62 | $54.30K | 161,569 |
| 667, L.P. Director, 10% owner | May 11, 2022 | Buy | +2,882 | $1.99 | $5.74K | 256,209 |
| 667, L.P. Director, 10% owner | May 11, 2022 | Buy | +22,983 | $1.99 | $45.74K | 2,528,583 |
| 667, L.P. Director, 10% owner | May 10, 2022 | Buy | +101,831 | $1.93 | $196.53K | 1,747,506 |
| 667, L.P. Director, 10% owner | May 10, 2022 | Buy | +40,800 | $1.70 | $69.36K | 145,498 |
| 667, L.P. Director, 10% owner | May 10, 2022 | Buy | +758,094 | $1.95 | $1.48M | 2,505,600 |
| 667, L.P. Director, 10% owner | May 10, 2022 | Buy | +95,060 | $1.95 | $185.37K | 253,327 |
| 667, L.P. Director, 10% owner | May 10, 2022 | Buy | +12,769 | $1.93 | $24.64K | 158,267 |
| 667, L.P. Director, 10% owner | May 10, 2022 | Buy | +325,373 | $1.70 | $553.13K | 1,645,675 |
| Brian M. Silver Chief Financial Officer | Mar 24, 2022 | Buy | +15,000 | $3.40 | $51.00K | 26,885 |
| David P. Southwell Chief Executive Officer, Director | Dec 23, 2021 | Option exercise | +48,670 | $1.97 | $95.88K | 146,569 |
| Zoran Zdraveski Chief Legal Officer | Sep 23, 2021 | Buy | +4,716 | $7.48 | $35.28K | 4,716 |
| Gavin MacBeath Chief Scientific Officer | Sep 21, 2021 | Buy | +57 | $6.19 | $353 | 49,767 |
| Brian M. Silver Chief Financial Officer | Sep 21, 2021 | Buy | +5,000 | $6.32 | $31.60K | 11,885 |
| Gavin MacBeath Chief Scientific Officer | Sep 20, 2021 | Buy | +4,943 | $6.22 | $30.75K | 49,710 |
| Brian M. Silver Chief Financial Officer | Sep 9, 2021 | Buy | +5,885 | $8.48 | $49.90K | 6,885 |
| David P. Southwell Chief Executive Officer, Director | Sep 8, 2021 | Buy | +11,000 | $8.73 | $96.03K | 97,899 |
| William Desmarais Chief Business Officer | Aug 27, 2021 | Buy | +2,500 | $9.08 | $22.70K | 2,500 |
| 667, L.P. Director | Jul 20, 2021 | Buy | +1,320,302 | $15.00 | $19.80M | 1,320,302 |
| 667, L.P. Director | Jul 20, 2021 | Buy | +104,698 | $15.00 | $1.57M | 104,698 |
| Timothy J. Barberich Director | Jul 20, 2021 | Conversion | +33,259 | – | – | 33,259 |
| Brian M. Silver Chief Financial Officer | Jul 20, 2021 | Buy | +1,000 | $15.00 | $15.00K | 1,000 |
| Christoph H. Westphal 10% owner | Jul 20, 2021 | Buy | +133,333 | $15.00 | $2.00M | 1,278,838 |
| Christoph H. Westphal 10% owner | Jul 20, 2021 | Conversion | +1,145,505 | – | – | 1,145,505 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of TScan Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 38,486 shares on Oct 13, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Zoran Zdraveski Officer | Aug 23, 2024 | 164,686 | $905.77K | Aug 23, 2024 | STOCK OPTION EXERCISE |
| Southwell David P Director | May 15, 2023 | 85,911 | $346.22K | May 15, 2023 | Open Market |
See a number that looks wrong?